Viskase Holdings, Inc. (VISK)
| Market Cap | 64.49M |
| Revenue (ttm) | 349.56M -10.2% |
| Net Income | -43.41M |
| EPS | -0.32 |
| Shares Out | 14.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250 |
| Open | 4.500 |
| Previous Close | 4.500 |
| Day's Range | 4.500 - 4.500 |
| 52-Week Range | 0.015 - 8.550 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Viskase Holdings
Viskase Holdings, Inc., together with its subsidiaries, produces and sells non-edible cellulosic, fibrous, and plastic casings for preparing and packaging processed meat products and services in North America, South America, Europe, Asia, and internationally. The company offers NOJAX cellulose casings for use in the automated production of hot dogs, dry mini salamis, and cooked and coarse ground sausages; and large cellulose casings to give cylindrical or oval shape to the processed meats that are used in bologna, mortadella, deli ham, bierwurs... [Read more]
Financial Performance
In 2025, Viskase Holdings's revenue was $364.36 million, a decrease of -9.76% compared to the previous year's $403.78 million. Losses were -$65.49 million, 1121.9% more than in 2024.
Financial StatementsNews
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has completed its previously announced exchange offer to...
Enzon Announces Reverse Stock Split
CRANFORD, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that the previously approved 1-for-100 reverse stock split will...
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
CRANFORD, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer ...
Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”) involving ...
Enzon and Viskase Announce Amendment to Merger Agreement
Enzon and Viskase stockholders will respectively own 45% and 55% of the combined company Enzon and Viskase stockholders will respectively own 45% and 55% of the combined company
Enzon and Viskase Enter into Merger Agreement
Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the com...
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Com...
Enzon Pharmaceuticals Announces Results of Rights Offering
Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previous...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting...
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders
CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights o...
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value
CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits p...